

AMENDMENTS TO THE CLAIMS

1-81. (Canceled)

82. (Currently amended) A method for reducing antigen-specific T cell responsiveness ~~in vivo to an autoantigen-expressing cell~~, which method comprises administering to a subject in need of such treatment:

(a) an antigen-presenting cell that presents an autoantigen to an activated T cell expressing mouse or human gp39; and

(b) an anti-gp39 antibody which binds to ~~an antigen~~ mouse or human gp39 on the activated T cell, ~~which antigen~~:

(i) ~~is bound by a CD40 immunoglobulin (CD40-Ig) fusion protein;~~

(ii) ~~is present on activated but not resting T cells; and~~

(iii) ~~has the same molecular weight as a protein precipitated by the CD40-Ig fusion protein;~~

wherein the anti-gp39 antibody is administered prior to, concurrent with, or subsequent to administration of the antigen-presenting cell in an amount effective to reduce T cell responsiveness to the antigen-presenting cell.

83. (Previously presented) The method of claim 82, wherein the antigen-presenting cell is selected from the group consisting of B lymphocytes, monocytes, dendritic cells, Langerhans cells, keratinocytes, endothelial cells, astrocytes, fibroblasts and oligodendrocytes.

84. (Previously presented) The method of claim 82, wherein the antigen-presenting cell is a B lymphocyte.

85. (Previously presented) The method of claim 84, wherein the B lymphocyte is an activated B lymphocyte.

86. (Previously presented) The method of claim 85, wherein the activated B lymphocyte is a splenic activated B lymphocyte.

87. (Previously presented) The method of claim 82, wherein the antigen-presenting cell is a lymphoid cell.

88. (Previously presented) The method of claim 82, wherein the antigen-presenting cell is a peripheral blood lymphocyte.

89. (Previously presented) The method of claim 82, wherein the antigen-presenting cell is a bone marrow lymphocyte.

90. (Previously presented) The method of claim 82, wherein the antigen-presenting cell is a Langerhans cell.

91. (Previously presented) The method of claim 82, wherein the antigen-presenting cell is a dendritic cell.

92. (Previously presented) The method of claim 82, wherein the anti-gp39 antibody is an anti-human anti-gp39 antibody.

93. (Previously presented) The method of claim 92, wherein the anti-human anti-gp39 antibody is humanized.

94. (Previously presented) The method of claim 92, wherein the anti-human anti-gp39 antibody is a chimeric anti-human anti-gp39 antibody containing human constant regions.